Adam Rosenthal, Star Therapeutics CEO

A new start­up sets course against a con­stel­la­tion of rare dis­eases with a first shot re­pur­pos­ing the SIRP path­way

De­spite some big ad­vances in re­cent years, rare dis­ease re­mains a most­ly un­chart­ed wilder­ness with many pa­tients left un­der­served. A start­up with galac­tic am­bi­tions now …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.